We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Oxycodone Assay Added to Drugs of Abuse Test Menu

By LabMedica International staff writers
Posted on 29 Apr 2009
A drug of abuse test menu has been expanded to include an oxycodone enzyme immunoassay. The assay is for the qualitative and semiquantitative determination of oxycodone and its metabolite, oxymorphone, in human urine.

Reagents and calibrators for the oxycodone assay are liquid and ready-to-use, which eliminates the need for mixing, hydrating, or prediluting reagents before testing.

Drugs of Abuse Test (DAT) assays are available through Beckman Coulter (Nyon, Switzerland) They are specifically engineered, formulated, and packaged to provide the critical elements of effective DAT analysis--speed, accuracy, ease-of-use, and economy. The assays, when used in conjunction with Synchron and UniCel clinical chemistry systems, provide timely, reliable and efficient DAT results.

Oxycodone is a semisynthetic opioid prescribed for pain management in patients with moderate to severe pain. This narcotic pain reliever is similar to codeine and morphine in its analgesic properties, but is more potent than morphine and has greater potential for dependence. It is supplied as OxyContin (Oxycodone HCI), or in combination with aspirin (Percodan) or acetaminophen (Percocet). The pills are often crushed into a powder and inhaled for a faster effect, which can have a fatal outcome.

Related Links:
Beckman Coulter



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN

Latest Clinical Chem. News

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
29 Apr 2009  |   Clinical Chem.

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
29 Apr 2009  |   Clinical Chem.

Low-Cost Portable Screening Test to Transform Kidney Disease Detection
29 Apr 2009  |   Clinical Chem.